Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002; 16:1045–1052.
-
2.
Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996; 88:1046–1051.
-
3.
Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87:265–272.
-
4.
Relander T, Johnson NA, Farinha P, et al. Prognostic factors in follicular lymphoma (Erratum published in J Clin Oncol 2010; 28:4664). J Clin Oncol 2010; 28:2902–2901.
-
5.
Milner AE, Grand RJ, Vaughan AT, et al. Differential effects of BCL-2 on survival and proliferation of human B-lymphoma cells following gamma-irradiation. Oncogene 1997; 15:1815–1822.
-
6.
Mirkovic N, Voehringer DW, Story MD, et al. Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene 1997; 15:1461–1470.
-
7.
Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81:151–157.
-
8.
Bodei L, Paganelli G, Mariani G. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. J Nucl Med 2006; 47:375–377.
-
9.
Waser B, Tamma ML, Cescato R, et al. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009; 50:936–941.
-
10.
Ferone D, Resmini E, Boschetti M, et al. Potential indications for somatostatin analogues: immune system and limphoproliferative disorders. J Endocrinol Invest 2005; 28:111–117.
-
11.
Reubi JC, Laissue J, Krenning E, et al. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992; 43:27–35.
-
12.
Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24:389–427.
-
13.
Villamil JA, Henry CJ, Hahn AW, et al. Hormonal and sex impact on the epidemiology of canine lymphoma [published online ahead of print Mar 14, 2010]. J Cancer Epidemiol doi:10.1155/2009/591753.
-
14.
Rassnick KM, McEntee MC, Erb HN, et al. Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma. J Vet Intern Med 2007; 21:1364–1373.
-
15.
Simon D, Moreno SN, Hirschberger J, et al. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. J Am Vet Med Assoc 2008; 232:879–885.
-
16.
Brodsky EM, Maudlin GN, Lachowicz JL, et al. Asparaginase and MOPP treatment of dogs with lymphoma. J Vet Intern Med 2009; 23:578–584.
-
17.
Rosenberg MP, Matus RE, Patnaik AK. Prognostic factors in dogs with lymphoma and associated hypercalcemia. J Vet Intern Med 1991; 5:268–271.
-
18.
Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993; 7:289–295.
-
19.
Dobson JM, Blackwood LB, McInnes EF, et al. Prognostic variables in canine multicentric lymphosarcoma. J Small Anim Pract 2001; 42:377–384.
-
20.
Tomiyasu H, Goto-Koshino Y, Takahashi M, et al. Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. J Vet Med Sci 2010; 72:1165–1172.
-
21.
Jia F, Figueroa SD, Gallazzi F, et al. Molecular imaging of bcl-2 expression in small lymphocytic lymphoma using 111In-labeled PNA-peptide conjugates. J Nucl Med 2008; 49:430–438.
-
22.
de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998; 58:437–441.
-
23.
Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003; 24:28–47.
-
24.
Nyland TG, Hager DA, Herring DS. Sonography of the liver, gallbladder, and spleen. Semin Vet Med Surg (Small Anim) 1989; 4:13–31.
-
25.
Feeney DA, Johnston GR, Hardy RM. Two-dimensional, grayscale ultrasonography for assessment of hepatic and splenic neoplasia in the dog and cat. J Am Vet Med Assoc 1984; 184:68–81.
-
26.
Wrigley RH, Konde LJ, Park RD, et al. Ultrasonographic features of splenic lymphosarcoma in dogs: 12 cases (1980–1986). J Am Vet Med Assoc 1988; 193:1565–1568.
-
27.
Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002; 16:704–709.
-
28.
Lewis MR, Jia F, Gallazzi F, et al. Radiometal-labeled peptide-PNA conjugates for targeting bcl-2 expression: preparation, characterization, and in vitro mRNA binding. Bioconjug Chem 2002; 13:1176–1180.
-
29.
Lambrechts AC, Hupkes PE, Dorssers LC, et al. Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. J Clin Oncol 1994; 12:1541–1546.
-
30.
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503–511.
-
31.
Stacchini A, Aragno M, Vallario A, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999; 23:127–136.
-
32.
Vanhagen PM, Krenning EP, Reubi JC, et al. Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haematol 1993; 83:75–79.
Advertisement
Evaluation of a B-cell leukemia-lymphoma 2-specific radiolabeled peptide nucleic acid–peptide conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma
Abstract
Objective—To evaluate use of a radiolabeled peptide nucleic acid–peptide conjugate (RaPP) targeting B-cell leukemia-lymphoma 2 (BCL2) mRNA for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma and to assess associations among RaPP uptake, time to tumor progression (TTP), and BCL2 mRNA expression.
Animals—11 dogs with B-cell lymphoma and 1 clinically normal dog.
Procedures—Scintigraphic images were acquired 1 hour after IV injection of the RaPP. Regions of interest (ROIs) were drawn around lymph nodes, liver, and spleen; ROI intensity (relative to that of an equally sized region of muscle in the same image) was measured. Each ROI was also subjectively categorized as positive or negative for increased RaPP uptake. Expression of BCL2 mRNA was determined via quantitative reverse transcriptase PCR assay of a lymph node sample from dogs with lymphoma. Associations among imaging results, TTP, and BCL2 mRNA expression were evaluated.
Results—Increased RaPP uptake was detected in affected tissues of dogs with lymphoma. Dogs with superficial cervical lymph node ROIs categorized as negative (n = 8) for increased RaPP uptake had a significantly longer TTP than did dogs for which this ROI was considered positive (2). Measured intensity of mandibular and superficial cervical lymph node ROIs was negatively associated with TTP. Associations among BCL2 mRNA and ROI intensity or TTP were not significant.
Conclusions and Clinical Relevance—Increased RaPP uptake at mandibular or superficial cervical lymph node ROIs may be a negative prognostic indicator in dogs with lymphoma. A larger investigation is needed to determine clinical value of the RaPP for disease detection and prognostication.
Contributor Notes
Supported by National Institutes of Health Grant No. CA103130 and Veterans Administration Grant No. BX000575.
Powered by PubFactory